{"result": "(\"entity\"<|>RUZ-PONS<|>PERSON<|>Ruz-Pons is an author referenced in the context of nutritional treatment for β-oxidation disorders, specifically in relation to Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel Gutiérrez-Solana is a researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>Miguel G", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: amien-                          grasos saturados de cadena muy larga (ácido hexaco-\nto nutricional en las alteraciones de la β-oxidación de\nlos ácidos grasos31.                                                           sanoico, C26:0) o la ratio ácido tetracosanoico:ácido\n                                                                               docosanoico (C24:0:C22:0), o la ratio hexacosanoico:\n\n\n\nTabla 3.   Resumen del tratamiento nutricional de las alteraciones de la β-oxidación de los ácidos grasos (tomado de\nRuiz-Pons M31)\n                            Medidas generales                   Lípidos /               Lípidos / aportes                Medidas especiales\n                                                              restricciones\n  Trastornos de la         Evitar ayuno                   TCL 10 % energía            TCM: 2-3 g/kg/día en            DHA: 65 mg/día (en\n  β-oxidación de           Nutrición enteral              total                       menores de 1 año                menores de 20 kg) y\n  cadena larga y           nocturna en casos                                          TCM: 1-1,25 g/kg/día            130 mg/día (mayores de\n  muy larga                graves, almidón de                                         en mayores de 1 año             20 kg) o aceite de nuez\n                           maíz, carbohidratos                                                                        En debilidad muscular\n                           de absorción lenta                                                                         o rabdomiólisis:\n                           Aceite de soja                                                                             carbohidratos y/o TCM a\n                           (precursor ácidos                                                                          la dosis de 0,25-0,5 g/kg\n                           grasos esenciales)                                                                         20 minutos antes del\n                           Distribución                                                                               ejercicio\n                           calórica: TCM + TCL                                                                        Montorizar ácidos grasos\n                           20-30 % máximo                                                                             esenciales y vitaminas\n                                                                                                                      liposolubles\n  Trastornos de la         Evitar ayuno                   TCM contraindicado          Módulos de lípidos              Ingesta de azúcares\n  β-oxidación de           Nutrición enteral                                          sin TCM, mezcla libre           complejos antes del\n  cadena media             nocturna en casos                                          de grasa                        ayuno, esfuerzo o\n                           graves, almidón de                                         Lípidos: 30 % del               estrés por el riesgo de\n                           maíz, carbohidratos                                        valor calórico total            rabdomiólisis\n                           de absorción lenta                                                                         No limitar la actividad\n                           en los primeros                                                                            física\n                           meses de vida                                                                              No se aconsejan medidas\n                           Cuando la edad lo                                                                          dietéticas restrictivas en\n                           permita, azúcares                                                                          el niño mayor y adulto,\n                           complejos                                                                                  salvo en crisis agudas\nTCL: triglicéridos de cadena larga; TCM: triglicéridos de cadena media.\n---\n                              Tema 20.     Trastornos congénitos del metabolismo de los lípidos: Adrenoleucodistrofia…                        351\n\n\n\nácido docosanoico (C26:0:C22:0). Además, el hallazgo                           2.  Girós M, Gutiérrez-Solana L, Pedrón C, Coll J, Pine-\nde lesiones en la resonancia magnética cerebral y la                               da M, Campistol J et al. Protocolo de diagnóstico,\npresencia     de   insuficiencia     suprarrenal     confirman      el             tratamiento y seguimiento de Adrenoleucodistro-\ndiagnóstico. En la actualidad se puede realizar el análi-                          fia ligada al cromosoma X. Asociación Española\nsis genético de mutaciones del gen de la ALD, y es po-                             para el Estudio de los Errores Congénitos del Me-\nsible el diagnóstico prenatal.                                                     tabolismo.      En:  http://ae3com.eu/protocolos/pro-\n   El tratamiento de la ALD incluye: tratamiento sinto-                            tocolo6.pdf\nmático, tratamiento esteroideo sustitutivo, y una serie                        3.  Moser HW. Dietary management of X-linked adre-\nde tratamientos que incluyen el abordaje dietético.                                noleukodystrophy. Annu Rev Nutr 1995; 15: 379-\n   El tratamiento dietético consiste en la restricción de                          397.\nla ingesta de ácidos grasos de cadena muy larga, com-                          4.  Migeon BR, Moser HW, Moser AB, Axelman J, Si-\nbinado con la suplementación oral de aceite de Loren-                              llence D, Norum RA. Adrenoleukodystrophy: evi-\nzo (mezcla de gliceril trioleato y gloceriltrierucato en                           dence for X-linkage, inactivation and selection fa-\nproporción 4:1), que consigue normalizar las concen-                               vouring the mutant allele in heterozygous cells.\ntraciones plasmáticas de ácidos grasos de cadena muy                               Proc Natl Acad Sci USA 1981; 78: 5066-5070.\nlarga. Los\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>ADRENOLEUCODISTROFIA<|>EVENT<|>Adrenoleucodistrofia is a genetic disorder affecting lipid metabolism, specifically linked to the X chromosome, which can be diagnosed through genetic analysis and has dietary management as part of its treatment.)\n##\n(\"entity\"<|>ASOCIACIÓN ESPAÑOLA PARA EL ESTUDIO DE LOS ERRORES CONGÉNITOS DEL METABOLISMO<|>ORGANIZATION<|>This organization focuses on the study and management of congenital metabolic errors, including providing protocols for diagnosis and treatment of conditions like Adrenoleucodistrofia.)\n##\n(\"entity\"<|>ACEITE DE LORENZO<|>ORGANIZATION<|>A dietary supplement used in the treatment of Adrenoleucodistrofia, consisting of a mixture of glycerol trioleate and glycerol trierucate.)\n##\n(\"entity\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>PERSON<|>A researcher involved in the study and treatment protocols for Adrenoleucodistrofia.)\n##\n(\"entity\"<|>TRIGLICÉRIDOS DE CADENA LARGA<|>EVENT<|>Triglycerides of long-chain fatty acids are dietary components that need to be restricted in patients with Adrenoleucodistrofia.)\n##\n(\"entity\"<|>TRIGLICÉRIDOS DE CADENA MEDIA<|>EVENT<|>Medium-chain triglycerides are dietary components that are contraindicated in certain cases of Adrenoleucodistrofia.)\n##\n(\"relationship\"<|>MIGUEL GUTIÉRREZ-SOLANA<|>ASOCIACIÓN ESPAÑOLA PARA EL ESTUDIO DE LOS ERRORES CONGÉNITOS DEL METABOLISMO<|>Miguel Gutiérrez-Solana is associated with the organization that studies congenital metabolic errors, including Adrenoleucodistrofia<|>7)\n##\n(\"relationship\"<|>ADRENOLEUCODISTROFIA<|>ASOCIACIÓN ESPAÑOLA PARA EL ESTUDIO DE LOS ERRORES CONGÉNITOS DEL METABOLISMO<|>The organization provides protocols for the diagnosis and treatment of Adrenoleucodistrofia<|>8)\n##\n(\"relationship\"<|>ADRENOLEUCODISTROFIA<|>ACEITE DE LORENZO<|>Oil of Lorenzo is used as a dietary treatment for managing Adrenoleucodistrofia<|>9)\n##\n(\"relationship\"<|>TRIGLICÉRIDOS DE CADENA LARGA<|>ADRENOLEUCODISTROFIA<|>Long-chain triglycerides need to be restricted in the diet of patients with Adrenoleucodistrofia<|>8)\n##\n(\"relationship\"<|>TRIGLICÉRIDOS DE CADENA MEDIA<|>ADRENOLEUCODISTROFIA<|>Medium-chain triglycerides are contraindicated in the dietary management of Adrenoleucodistrofia<|>8)\n<|COMPLETE|>"}]}